NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors

NCT05593094

Active Not RecruitingPhase 1, Phase 2

Sponsor: Hoffmann-La Roche

Conditions: Advanced Solid Tumors, HER2-positive Breast Cancer

Interventions: ZN-A-1041, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b, ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b, ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b, ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c

Countries: United States, Australia, France, Italy, New Zealand, Spain, United Kingdom

This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases. The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).

Eligibility overview

Sex: ALL

Age: 18 Years to

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Life expectancy of at least 6 months, as determined by the investigator
* Histologically or cytologically confirmed with unresectable or metastatic HER2-positive advanced solid tumors
* Must be relapsed or refractory after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received first-line induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen
* Participants with new, untreated, progressive, or stable brain metastases are eligible

Exclusion Criteria:

* Participation in any other clinical study involving an investigational drug or device within 4 weeks prior to the first dose of study treatment
* Any intracranial lesion (brain metastasis) that requires immediate local therapy, such as surgery or radiation, or systemic corticosteroids at the time of enrollment
Locations (36)
  • Tucson, Arizona, United States
  • Cerritos, California, United States
  • San Francisco, California, United States
  • Boston, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Detroit, Michigan, United States
  • Durham, North Carolina, United States
  • Houston, Texas, United States
  • Geelong, Victoria, Australia
  • St Albans, Victoria, Australia
  • Toulouse, Haute-Garonne, France
  • Dijon, France
  • Lille, France
  • Lyon, France
  • Marseille, France
  • Saint-Herblain, France
  • Villejuif, France
  • Parma, Emilia-Romagna, Italy
  • Bergamo, Lombardy, Italy
  • Magnago, Lombardy, Italy
  • Auckland, New Zealand
  • Argentona, Barcelona, Spain
  • Santiago de Compostela, LA Coruna, Spain
  • A Gudiña, Orense, Spain
  • Las Cabezas de San Juan, Sevilla, Spain
  • Barcelona, Spain
  • Barcelona, Spain
  • Jaén, Spain
  • Madrid, Spain
  • Madrid, Spain
  • + 6 more on CT.gov